Lilly Buying Spree Surpasses $32B
Bloomberg’s Madison Muller joins Dani Burger on “Bloomberg Deals.” Eli Lilly agreed to buy closely held Calytrix Bio in a deal that could be worth up to $1.5 billion, the latest in the drugmaker’s $32 billion wave of acquisitions in 2026 as it builds out its cancer and immunology businesses. (Source: Bloomberg)
This story was published by Bloomberg. Read the full article on their site.
Read the full story at bloomberg.com(opens in a new tab)







